AiCure launches “digital biomarker” app for clinical trialsArtificial intelligence company AiCure has launched a digital tool that detects subtle changes in a patient’s condition that Share XAiCure launches “digital biomarker” app for clinical trialshttps://pharmaphorum.com/news/aicure-launches-digital-biomarker-app-for-clinical-trials/
Immuno-oncology latecomer GSK shows off PD-1 drug dataGlaxoSmithKline has new data showing that its cancer immunotherapy dostarlimab works as a second-line treatment for women with Share XImmuno-oncology latecomer GSK shows off PD-1 drug datahttps://pharmaphorum.com/news/immuno-oncology-latecomer-gsk-shows-off-pd-1-drug-data/
Pfizer, BioNTech aim to start German COVID-19 vaccine trial this monthPfizer and BioNTech are in pole position to start the first human trial of a COVID-19 vaccine in Share XPfizer, BioNTech aim to start German COVID-19 vaccine trial this monthhttps://pharmaphorum.com/news/pfizer-biontech-aim-to-start-german-covid-19-vaccine-trial-this-month/
Oxford Uni coronavirus vaccine trial could begin this weekUniversity of Oxford researchers are due to start dosing healthy volunteers in a clinical trial of their coronavirus Share XOxford Uni coronavirus vaccine trial could begin this weekhttps://pharmaphorum.com/news/uk-coronavirus-vaccine-trial-could-begin-this-week/
Gilead slides as second Chinese trial of remdesivir is stoppedTwo investigator-led phase 3 trials of Gilead Sciences’ coronavirus candidate remdesivir have now been halted because they weren’t Share XGilead slides as second Chinese trial of remdesivir is stoppedhttps://pharmaphorum.com/news/gilead-slides-as-two-chinese-trials-of-remdesivir-are-stopped/
AZ, Lilly join efforts to develop drugs for COVID-19AstraZeneca and Eli Lilly have joined the ranks of drugmakers around the world trying to repurpose existing drugs Share XAZ, Lilly join efforts to develop drugs for COVID-19https://pharmaphorum.com/news/az-lilly-join-efforts-to-develop-drugs-for-covid-19/
First study of Gilead’s remdesivir in COVID-19 reveals littleTwo-thirds of coronavirus patients treated with Gilead’s antiviral drug remdesivir seemed to get a clinical benefit from the Share XFirst study of Gilead’s remdesivir in COVID-19 reveals littlehttps://pharmaphorum.com/news/first-study-of-gileads-remdesivir-in-covid-19-reveals-little/
AZ firms up immuno-oncology imaging deal with ImaginAbAstraZeneca has expanded its alliance with ImaginAb, an imaging specialist developing imaging agents to increase the efficacy and Share XAZ firms up immuno-oncology imaging deal with ImaginAbhttps://pharmaphorum.com/news/az-firms-up-immuno-oncology-imaging-deal-with-imaginab/
Despite benefits, blockchain adoption is slow in life sciences, says reportWidespread adoption of blockchain could add $3 billion-worth of value to life sciences companies by 2025, but adoption Share XDespite benefits, blockchain adoption is slow in life sciences, says reporthttps://pharmaphorum.com/news/despite-benefits-blockchain-adoption-is-slow-in-life-sciences-says-report/
